How Healthcare IT Companies Are Actually Valued
Healthcare IT is not a single market — it's at least five distinct sub-segments that trade on completely different multiples and to completely different buyers. Lumping EMR vendors, RCM platforms, care-coordination tools, clinical-decision-support, and payer-tech into one "HIT" bucket is the fastest way to mis-price a transaction. Below is how I actually triangulate what a company is worth.
Sub-Segment Drives Almost Everything
EMR / EHR platforms (Athena, eClinicalWorks, Greenway, Practice Fusion-style): These trade as sticky, mission-critical infrastructure. Switching costs are enormous, gross retention sits in the high 90s, but growth is mature. Public comps are limited — Athenahealth went private at ~$17B (Bain / Veritas, 2022) and Cerner sold to Oracle for $28B in 2022 at roughly 5x revenue. Mid-market EMR platforms trade 6-10x revenue, premium leaders 10-14x.
Revenue Cycle Management (Athenahealth's RCM arm, R1 RCM, Privia-style platforms): RCM trades on a blend of revenue and EBITDA. The economics are services-heavy with software wrapping — so multiples sit lower than pure SaaS, typically 3-7x revenue or 10-15x EBITDA. Outsourced RCM with high-margin tech leverage gets to the higher end; people-heavy BPO-style RCM trades closer to staffing-business multiples (5-9x EBITDA).
Care coordination and population health (Innovaccer, Bamboo Health, Arcadia): This is where the premium multiples live. Innovaccer raised at a $3.4B valuation. Bamboo Health sold to Kohlberg & Company in 2023. These platforms trade 10-18x revenue if they have payer distribution and 6-10x revenue if they're still proving the channel.
Clinical decision support and life-sciences tech (Veeva, Doximity, Omnicell): Veeva (VEEV) trades around 12-15x revenue and ~26x EBITDA on the public markets — it's the anchor comp for premium vertical-SaaS healthcare. Private vertical leaders trade 8-14x revenue depending on growth and gross-margin profile.
Payer-tech and digital health enablement:Wide range. Strategically valuable assets (prior-auth automation, claims-edit AI) trade 8-15x revenue. Generic engagement tools and care-management point solutions trade 3-6x revenue. Buyer concentration risk is the killer here — if 60% of revenue comes from two payers, the multiple compresses fast.
What Buyers Actually Diligence
Customer concentration in payer or provider.Healthcare IT companies routinely have one or two anchor customers driving 30%+ of revenue. Buyers underwrite this aggressively — they want to see contract length, renewal terms, and the operational depth of the integration. Concentrated revenue with multi-year terms and deep workflow integration is fine. Concentrated revenue on month-to-month contracts kills deals.
Compliance moat.HIPAA is table stakes. SOC 2 Type II is the institutional minimum. HITRUST CSF certification is what separates the premium tier — payers and large health systems will not buy without it, so HITRUST is genuine pricing power. Buyers will pay up for it because re-certifying a target post-close is a 12-18 month exercise.
Net revenue retention. The bar for a premium multiple is 110%+ NRR. The best vertical SaaS companies in healthcare IT (Veeva-style) run 115-125%. Below 100% NRR and buyers question the underlying product fit; the multiple compresses 2-4 turns.
Implementation revenue mix.Healthcare IT has historically been heavy on services revenue (implementation, customization, integration). Buyers strip services revenue out of the multiple calculation — they only pay SaaS multiples on subscription revenue. A company with 60% subscription / 40% services trades materially worse than a 90% subscription company at the same total revenue.
Interoperability and FHIR maturity. Post-21st Century Cures Act, the ability to support FHIR APIs, USCDI data classes, and bulk-data exports is increasingly diligenced. Companies architected on legacy HL7-only integration are seeing buyer pushback.
The Numbers from Our Database
We've tracked 483 healthcare-IT transactions, 321 of them in the last few years. The recent-period median EV/EBITDA sits at 17.3x with the P25-P75 range running 12.4-21.5x. On revenue, recent median is 4.4x with P25-P75 of 2.5-7.5x. The size brackets matter enormously: sub-$25M deals trade 5-9x EBITDA, mid-market ($25-100M) trades 8-11x, and over-$500M deals trade 18-19x EBITDA — that gap reflects scale, distribution, and category leadership premium more than fundamental quality differences.
Active Buyers in Healthcare IT
Strategic acquirers: Oracle Health (post-Cerner), UnitedHealth / Optum, Veeva, Waystar, Olive (now restructuring), Greenway, athenahealth, and increasingly Microsoft Cloud for Healthcare. Financial buyers: Bain Capital, Veritas, Vista Equity, Thoma Bravo, KKR, Kohlberg, TPG, and growth-stage investors like General Atlantic, ICONIQ, and Insight Partners. The pace of PE roll-ups in care coordination, prior-auth automation, and RCM is the highest I've seen in a decade.